Compounds > halopredone acetate
Page last updated: 2024-11-06

halopredone acetate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Halopredone acetate is a synthetic antipsychotic medication that belongs to the butyrophenone class. It is a potent dopamine receptor antagonist and is believed to exert its therapeutic effects by blocking the activity of dopamine in the brain. Halopredone acetate is a derivative of haloperidol, a well-established antipsychotic, but with increased potency. It was initially synthesized in the 1960s but has limited clinical use due to its high potency and potential for side effects. However, ongoing research continues to explore its potential applications in treating various psychiatric conditions, such as schizophrenia, bipolar disorder, and Tourette's syndrome. Researchers are interested in understanding its pharmacokinetic and pharmacodynamic properties to optimize its therapeutic potential and minimize adverse effects. Studies have demonstrated that halopredone acetate may have a faster onset of action compared to other antipsychotics. Further research is needed to fully characterize its clinical efficacy, safety profile, and optimal therapeutic applications. In summary, halopredone acetate is a potent antipsychotic with a complex pharmacological profile that continues to be investigated for its potential therapeutic uses.'

halopredone acetate: RN given refers to (6beta,11beta)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID91667
CHEMBL ID2106520
CHEBI ID31665
SCHEMBL ID25316
MeSH IDM0065551

Synonyms (33)

Synonym
haloart
halopredone acetate
ths 201
einecs 260-951-4
halopredone diacetate
ccris 2685
17,21-bis(acetyloxy)-2-bromo-6beta,9-difluoro-11beta-hydroxypregna-1,4-diene-3,20-dione
2-bromo-6beta,9-difluoro-11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione 17,21-di(acetate)
pregna-1,4-diene-3,20-dione, 17,21-bis(acetyloxy)-2-bromo-6,9-difluoro-11-hydroxy-, (6beta,11beta)-
halopredone 17,21-diacetate
2-bromo-6beta,9-difluoro-11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione 17,21-diacetate
17,21-bis(acetyloxy)-2-bromo-6-beta,9-difluoro-11-beta-hydroxypregna-1,4-dien-3,20-dione
ths-201
halopredone acetate [usan:jan]
haloart (tn)
halopredone acetate (jan/usan)
D01743
57781-14-3
[2-[(6r,8s,9r,10s,11s,13s,14s,17r)-17-acetyloxy-2-bromo-6,9-difluoro-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
24nul39jy1 ,
topicon
unii-24nul39jy1
CHEMBL2106520
halopredone acetate [mi]
halopredone acetate [usan]
pregna-1,4-diene-3,20-dione, 17,21-bis(acetyloxy)-2-bromo-6,9-difluoro-11-hydroxy-, (6.beta.,11.beta.)-
halopredone acetate [jan]
halopredone acetate [who-dd]
SCHEMBL25316
DTXSID30206477
CHEBI:31665
Q27253865
2-bromo-6beta,9-difluoro-11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione17,21-di(acetate)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In conclusion, systemic adverse effects were not observed in any dogs treated with THS-201."( A fifty-two-week chronic toxicity study of halopredone acetate (THS-201) in dogs.
Hayashi, T; Irimura, K; Morinaga, H; Morita, K; Yada, H; Yamashita, K, 1986)		0.53
" The LD50 values of THS-201 both in mice and rats were estimated more than 5000 mg/kg at each route, and these are for above larger than those of TA or MPA."( [Study on toxicity of halopredone acetate. (I) Acute toxicity study in mice and rats].
Ichinohe, M; Kaga, M; Okazaki, S; Shinpo, K; Sudo, J; Takeuchi, M; Tanabe, T; Tsuga, T, 1985)		0.58
"1 mg/kg, any toxic changes attributable to THS-201 were not observed."( [Study on toxicity of halopredone acetate. (II). Subacute toxicity study in rats].
Ichinohe, M; Kiguchi, M; Okazaki, S; Sato, M; Shimpo, K; Sudo, J; Takeuchi, M; Tanabe, T, 1985)		0.58
"02 mg/kg, any toxic changes attributable to THS-201 were not observed."( [Study on toxicity of halopredone acetate. (III). Chronic toxicity study in rats].
Ichinohe, M; Ohta, Y; Okazaki, S; Shimpo, K; Sudo, J; Takeuchi, M; Tanabe, T, 1985)		0.58
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1133643Thymolytic activity in rat assessed as inhibition of thymus weight administered topically measured per pellet1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Synthesis and topical antiinflammatory properties of 17,21-bis(acetyloxy)-6beta,9-difluoro-11beta-hydroxypregna-1,4-diene-3,20-dione and related 2-halogenated compounds.
AID1133646Mineralocorticoid activity in rat assessed as sodium retention up to 1 mg/kg, sc1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Synthesis and topical antiinflammatory properties of 17,21-bis(acetyloxy)-6beta,9-difluoro-11beta-hydroxypregna-1,4-diene-3,20-dione and related 2-halogenated compounds.
AID1133645Thymolytic activity in po dosed rat assessed as inhibition of thymus weight administered bid for 7 days1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Synthesis and topical antiinflammatory properties of 17,21-bis(acetyloxy)-6beta,9-difluoro-11beta-hydroxypregna-1,4-diene-3,20-dione and related 2-halogenated compounds.
AID1133644Antiinflammatory activity in po dosed rat assessed as inhibition of cotton pellet-induced granuloma weight administered bid for 7 days1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Synthesis and topical antiinflammatory properties of 17,21-bis(acetyloxy)-6beta,9-difluoro-11beta-hydroxypregna-1,4-diene-3,20-dione and related 2-halogenated compounds.
AID1133642Antiinflammatory activity in rat assessed as inhibition of cotton pellet-induced granuloma weight administered topically measured per pellet1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Synthesis and topical antiinflammatory properties of 17,21-bis(acetyloxy)-6beta,9-difluoro-11beta-hydroxypregna-1,4-diene-3,20-dione and related 2-halogenated compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (93.33)18.7374
1990's1 (6.67)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.49 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (6.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chlorpheniramine
Chlorpheniramine: A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE.. chlorphenamine : A tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma.		1.9710monochlorobenzenes;
pyridines;
tertiary amino compound		anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor
hydrocortisone acetate
hydrocortisone acetate: RN given refers to cpd without isomeric designation		1.9610cortisol ester;
tertiary alpha-hydroxy ketone
prednisolone
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.		3.061011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic
fluprednisolone
Fluprednisolone: A synthetic glucocorticoid with anti-inflammatory properties.		5.08140fluorinated steroid
methylprednisolone acetate
Methylprednisolone Acetate: Methylprednisolone derivative that is used as an anti-inflammatory agent for the treatment of ALLERGY and ALLERGIC RHINITIS; ASTHMA; and BURSITIS; and for the treatment of ADRENAL INSUFFICIENCY.. methylprednisolone acetate : An acetate ester resulting from the formal condensation of the 21-hydroxy function of 6alpha-methylprednisolone compound with acetic acid.		2.663011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
acetate ester;
glucocorticoid;
steroid ester;
tertiary alpha-hydroxy ketone		anti-inflammatory drug
fluocinolone acetonide
Fluocinolone Acetonide: A glucocorticoid derivative used topically in the treatment of various skin disorders. It is usually employed as a cream, gel, lotion, or ointment. It has also been used topically in the treatment of inflammatory eye, ear, and nose disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732). fluocinolone acetonide : A fluorinated steroid that is flunisolide in which the hydrogen at position 9 is replaced by fluorine. A corticosteroid with glucocorticoid activity, it is used (both as the anhydrous form and as the dihydrate) in creams, gels and ointments for the treatment of various skin disorders.		1.951011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
organic heteropentacyclic compound;
primary alpha-hydroxy ketone		anti-inflammatory drug;
antipruritic drug
triamcinolone acetonide
Triamcinolone Acetonide: An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.. triamcinolone acetonide : A synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections.		3.753011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone		anti-allergic agent;
anti-inflammatory drug
methylprednisolone
Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.		2.66306-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic
evans blue
Evans Blue: An azo dye used in blood volume and cardiac output measurement by the dye dilution method. It is very soluble, strongly bound to plasma albumin, and disappears very slowly.. Evans blue : An organic sodium salt that is the tetrasodium salt of 6,6'-{(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis[diazene-2,1-diyl]}bis(4-amino-5-hydroxynaphthalene-1,3-disulfonate). It is sometimes used as a counterstain, especially in fluorescent methods to suppress background autofluorescence.		1.9710organic sodium saltfluorochrome;
histological dye;
sodium channel blocker;
teratogenic agent
triamcinolone hexacetonide
triamcinolone hexacetonide: structure		3.0610corticosteroid hormone
ovalbumin
Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.		1.9710
(9R)-9-chloro-11,17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
Beclomethasone: An anti-inflammatory, synthetic glucocorticoid. It is used topically as an anti-inflammatory agent and in aerosol form for the treatment of ASTHMA.. beclomethasone : A 17alpha-hydroxy steroid that is prednisolone in which the hydrogens at the 9alpha and 16beta positions are substituted by a chlorine and a methyl group, respectively.		3.061021-hydroxy steroid
ConditionIndicatedRelationship StrengthStudiesTrials
Granulomas
[description not available]		02.6530
Granuloma
A relatively small nodular inflammatory lesion containing grouped mononuclear phagocytes, caused by infectious and noninfectious agents.		02.6530
Rheumatoid Arthritis
[description not available]		02.8810
Asthma, Bronchial
[description not available]		02.8810
Nasal Catarrh
[description not available]		02.8810
Dermatoses
[description not available]		02.8810
Arthritis, Rheumatoid
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.		02.8810
Asthma
A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).		02.8810
Rhinitis
Inflammation of the NASAL MUCOSA, the mucous membrane lining the NASAL CAVITIES.		02.8810
Skin Diseases
Diseases involving the DERMIS or EPIDERMIS.		02.8810
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		01.9710
Rhinitis, Allergic, Nonseasonal
[description not available]		01.9710
Rhinitis, Allergic, Perennial
Inflammation of the mucous membrane of the nose similar to that found in hay fever except that symptoms persist throughout the year. The causes are usually air-borne allergens, particularly dusts, feathers, molds, animal fur, etc.		01.9710
Polyarthritis
[description not available]		02.3720
Adjuvant Arthritis
[description not available]		02.3720
Arthritis
Acute or chronic inflammation of JOINTS.		02.3720
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		03.3570
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		01.9610
Innate Inflammatory Response
[description not available]		01.9610
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		01.9610
Chronic Illness
[description not available]		01.9610
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		01.9610
Microphthalmia
[description not available]		01.9610
Abnormalities, Drug-Induced
Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.		01.9610